Auvelity Prior Authorization Guide: Requirements by Payer (2025–2026)

Auvelity (dextromethorphan/bupropion) is the first oral NMDA receptor antagonist approved for major depressive disorder in adults. Its 2022 FDA approval opened a new mechanistic category — but prior authorization for it is complicated by a single structural fact that doesn’t affect most antidepressant PAs: the drug contains bupropion.

That one fact creates a documentation trap that payer reviewers and practices get wrong repeatedly. This guide covers what makes Auvelity PAs different, what each major payer requires, and how to navigate the bupropion-component issue when it matters.

Freshness notice: Auvelity PA criteria are in active flux — UHC tightened its step-therapy count in December 2025. Requirements below reflect policies as of June 2026. The “85% of lives covered” figure you may see in Axsome communications measures formulary presence, not accessible coverage — a patient on UHC is “covered” but still needs three antidepressant failures documented. Verify against each payer’s current published policy before submitting.

Why Auvelity PAs Are Different

Most antidepressant prior authorizations follow a simple step-therapy pattern: document two or three failed SSRIs or SNRIs, submit, get approved. Auvelity breaks that pattern in three specific ways:

The bupropion trap. Auvelity contains bupropion hydrochloride 105 mg per tablet — not the antidepressant dose, but bupropion nonetheless. Some payer policies list bupropion as a required step-therapy agent. A patient who is medically contraindicated to bupropion — seizure disorder, active anorexia, active bulimia — carries the same contraindication to the bupropion component in Auvelity, but a payer reviewer may still flag the missing bupropion trial without reading the clinical context. When bupropion appears as a required step and the patient can’t take it: document the contraindication explicitly and in the PA cover letter, not just in the medical record.

Step counts vary three-to-one across payers. Cigna requires one prior antidepressant failure. UHC requires three, each at least four weeks. BCBS/FEP requires two. These aren’t interpretive differences — they’re the actual policy. Submitting one failure to UHC results in a quick denial; knowing the number before submission is the whole game.

Pharmacy benefit, retail dispensing. Auvelity is a Part D drug dispensed at retail pharmacy — not an injectable, not a specialty-only product, no REMS program. Axsome offers the MOSAIC access program for PA assistance and savings support, but this is optional infrastructure, not a required dispensing channel.

FDA Approval and Indication

Approved: August 18, 2022 (NDA 213,684)

Indication: Major depressive disorder (MDD) in adults

Drug class: NMDA receptor antagonist / sigma-1 receptor agonist (dextromethorphan component) with a CYP2D6 inhibitor (bupropion component) to achieve therapeutic DXM exposure

Formulation: Dextromethorphan HBr 45 mg / bupropion HCl 105 mg extended-release bilayer tablet

Dosing: 45 mg/105 mg once daily for days 1–3 (titration), then 45 mg/105 mg twice daily (maintenance). Maximum: 2 tablets/day.

What Auvelity is NOT approved for: Bipolar depression. Pediatric MDD. The FDA label is MDD in adults — ensure the submitted diagnosis reflects this exactly.

The mechanism: dextromethorphan is an over-the-counter cough suppressant at low doses but an NMDA receptor antagonist at therapeutic antidepressant levels. The problem is that CYP2D6 metabolizes DXM rapidly, making oral therapeutic levels impossible without inhibiting that enzyme. Bupropion is a potent CYP2D6 inhibitor — at 105 mg twice daily, it raises DXM to the NMDA-antagonist range without requiring IV administration. The antidepressant effect is the DXM, not the bupropion.

Diagnosis Documentation

Required: DSM-5 major depressive disorder — single episode (F32.0–F32.5) or recurrent (F33.0–F33.41). Not adjustment disorder with depressed mood. Not bipolar depression.

PHQ-9 or HAM-D: Not required by any major commercial payer at PA submission (confirmed across Cigna, UHC, Aetna, BCBS). Documenting baseline PHQ-9 is good clinical practice and supports appeals, but it is not a PA gate.

Prior antidepressant trials: Document each failed drug separately — drug name, dose, weeks at dose, reason for stopping (lack of efficacy or intolerance). Reviewers count trials; make each one unambiguous.

Contraindications That Affect PA

If any of the following apply, document them explicitly — they are the clinical basis for bypassing any step-therapy requirement for bupropion specifically.

Who Covers Auvelity

Payer-Specific PA Requirements

Cigna / Evernorth

Sources: Cigna National Formulary Antidepressants Step Therapy (cnf_864); Employer Step Therapy Policy 1803, effective 1/1/2026

Coverage: Yes. Upgraded to Tier 2 preferred brand effective 1/1/2026. Step therapy–gated.

Criteria (all required):

• Age ≥18; DSM-5 MDD diagnosis
• Failure of one qualifying Step 1 antidepressant (any generic from: bupropion ER/SR, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine)
• No minimum trial duration specified in Cigna policy (auto-adjudicates at point of sale if the prior fill exists in claims)

Note — “High Impact Criteria” variant: Some Cigna employer plans apply a higher bar requiring two Step 1 agents rather than one. Verify which policy applies to the specific plan.

Bupropion is one option, not a mandate. A single sertraline failure satisfies the step — bupropion monotherapy is not required.

Auto-approval bypasses: Suicidal ideation; prior Auvelity use; agitation associated with Alzheimer’s dementia.

Approval duration: 1 year. No PHQ-9 required.

UnitedHealthcare / Optum

Source: UHC Clinical Pharmacy Program 2025 P 3044-16, “Step Therapy – Antidepressants,” effective 12/1/2025

Coverage: Yes. Tier 4 (highest commercial tier).

Criteria (all required):

• Age ≥18
• Failure of at least three qualifying antidepressants, each with a documented history of at least 4 weeks of therapy (from: bupropion, citalopram, duloxetine, escitalopram, fluoxetine, fluvoxamine, paroxetine, sertraline, venlafaxine IR/ER)
• No psychiatric evaluation or PHQ-9 required; documentation = drug name and trial date

Auto-approval path: If all three qualifying agents appear in claims history within the prior 180 days, UHC auto-processes at point of sale — no manual PA review. This is the highest-value documentation path. Obtain the patient’s 180-day pharmacy claims history before submitting a manual PA; it may convert a PA queue into an automatic fill.

Important: UHC raised the step count to three effective December 2025 (previously lower). Any PA built on older UHC criteria may be under-documented.

Approval duration: 12 months.

Aetna

Sources: 2026 Aetna Standard Plan formulary; 2026 Aetna Advanced Control Plan formulary

No standalone Aetna CPB exists for Auvelity. Unlike Spravato (esketamine), which has its own Aetna medical bulletin, Auvelity is managed purely at the formulary tier. Coverage is entirely plan-design dependent.

First step: identify which Aetna plan the patient has.

Standard Plan: Preferred Brand (PB) — no prior authorization, no step therapy. Fill at retail pharmacy at the Preferred Brand copay. No clinical documentation required to initiate therapy.

Advanced Control Plan: Non-formulary (NF) — not covered. The path here is a formulary exception, not a step-therapy PA. Submit a prescriber letter documenting medical necessity for Auvelity specifically (why covered formulary antidepressants are inadequate). This is a different workflow than step-therapy documentation.

BlueCross BlueShield / FEP

Source: FEP Blue Pharmacy Policy 5.60.058, effective 1/1/2025

Coverage: Yes.

Criteria:

• MDD diagnosis in an adult
• Inadequate response, intolerance, or documented contraindication to at least two different antidepressants (from: SSRI, SNRI, bupropion, mirtazapine, TCA)
• Quantity limit: 180 tablets per 90 days (equals label max of 2 tablets/day)

Bupropion is one eligible option in the two-failure list — not a mandatory separate requirement. Two SSRI failures satisfy the step.

Regional BCBS plans: Other regional BCBS licensees follow similar two-failure step therapy but criteria vary by plan. FEP Blue (federal employee plans, policy 5.60.058) is the most consistently documented. Pull the specific regional BCBS plan’s pharmacy coverage policy before submitting.

Approval duration: 12 months. No PHQ-9 required.

Medicare Part D

Sources: CMS-4180-F (protected class rule); Centene CP.PMN.284 (proxy for typical Part D step criteria); Medicare.gov 2026 cost structure

Coverage: Yes. Antidepressants are one of CMS’s six protected drug classes — every Part D plan must cover drugs in this class, and Auvelity’s broad formulary inclusion results from this mandate.

The most important Medicare rule:

Step therapy and prior authorization can only be applied to new starts. Under CMS-4180-F, Part D plans are prohibited from imposing step therapy or PA on a beneficiary who is already established on Auvelity. If the patient was on Auvelity before joining this plan, document prior use — the step edit should not fire.

For new starts (criteria based on typical Part D UM, Centene CP.PMN.284 as proxy):

• MDD diagnosis, age ≥18
• Failure of two prior formulary antidepressants, each at least 4 weeks at up to maximally tolerated doses (from: SSRI, SNRI, bupropion, mirtazapine)
• Dose cap: ≤2 tablets/day (≤90 mg DXM / ≤210 mg bupropion daily)
• Approval duration: 12 months
• Exception for contraindication/adverse effects to required step agents

Cost (2026): The donut hole is eliminated. Structure: deductible (up to $615) → initial coverage (≈25% coinsurance) → $2,100 annual OOP cap, after which the plan covers 100%. At Auvelity’s list price (~$850–$1,300/month), a non-LIS patient hits the $2,100 cap within the first few fills. LIS/Extra Help members: ≈$12.65 per brand fill.

Exception timeline: 72 hours (standard review); 24 hours (expedited when delay endangers health).

Tips for First-Pass Approval

1. Match the step count to the payer before submitting. Cigna = 1. BCBS/FEP = 2. UHC = 3 (each at least 4 weeks). Submitting fewer failures than the payer requires is the most common denial cause.

2. For UHC: check 180-day claims history first. If three qualifying antidepressants appear in the patient’s pharmacy claims in the past 180 days, UHC auto-approves at point of sale. Get the claims history before queuing a manual PA.

3. For Aetna: determine the plan design before doing anything. Standard Plan = fill it, no PA. Advanced Control = formulary exception letter, not step-therapy documentation. Two completely different processes.

4. Document each trial individually. Drug name, dose, weeks at dose, reason for stopping. Reviewers count — make each trial unambiguous.

5. Document bupropion contraindication if it applies. If the patient has a seizure disorder, eating disorder, or MAOI history, state this explicitly in the PA as the basis for bypassing any step-therapy requirement for bupropion.

6. For Medicare: establish new-start vs. existing therapy. Prior Auvelity use is a complete bypass of the step-therapy gate under CMS protected-class rules. Document any prior fills, even from commercial insurance before Medicare enrollment.

7. MDD diagnosis must be DSM-5 MDD. Confirm the ICD-10 code is F32.x or F33.x. Bipolar depression (F31.x) will be denied — it is not on the FDA label.

8. Axsome MOSAIC program provides PA support, copay assistance, and samples for eligible patients. Not a substitute for PA documentation, but useful for access while PA is in review.

When the PA Fails

Sources

• FDA Approval Letter, Auvelity (NDA 213,684), August 18, 2022
• Cigna National Formulary Antidepressants Step Therapy Policy (cnf_864)
• Cigna Employer Step Therapy Policy 1803, effective 1/1/2026
• UHC Clinical Pharmacy Program 2025 P 3044-16, “Step Therapy – Antidepressants,” effective 12/1/2025
• FEP Blue Pharmacy Policy 5.60.058 — Auvelity (dextromethorphan and bupropion), effective 1/1/2025
• Centene Clinical Policy CP.PMN.284, effective 12/1/2022, reviewed 11/2025
• CMS-4180-F, Medicare Advantage and Part D Drug Pricing Final Rule — six protected classes, new-start step-therapy restriction
• DailyMed, Auvelity prescribing information (setid: dcefda7c-9a68-278e-e053-2995a90aec79)
• Axsome Therapeutics Q3 2025 Financial Results — formulary coverage statistics

PA requirements update frequently. This guide was last reviewed June 2026. Always verify against each payer’s current published policy before submitting.